ライフサイエンスコーパス: arginine vasopressin

1 with placebo was 54 +/- 4 mins (p < .05 vs. arginine vasopressin).

2 dipsia with the use of dDAVP (1-desamino-8-D-arginine-vasopressin).

3 d to monitor real-time exocytosis induced by arginine vasopressin.

4 V(2)-antagonist d(CH(2))(5)[D-Ile(2), Ile(4)]arginine vasopressin.

5 d affiliative behaviour after injection with arginine vasopressin.

6 uding thapsigargin, ionomycin, caffeine, and arginine vasopressin.

7 The immature kidney is resistant to arginine vasopressin.

8 receptors for gastrin-releasing peptide and arginine vasopressin.

9 ized following stimulation with the agonist, arginine-vasopressin.

10 ton smoke), or an injured group treated with arginine vasopressin (0.02 IU.min(1)) from 1 hr after in

11 Arginine vasopressin (0.1 and 1.0 nM), endothelin-1 (10

12 urvivors (n = 10) received a bolus of either arginine vasopressin (0.2 units/kg) or placebo during th

13 itated over 60 mins with saline (8.5 mL/kg), arginine vasopressin (0.4 IU/kg bolus plus 0.08 IU x kg

14 Treatment with IV 1-deamino-8-D-arginine vasopressin (0.4 ug/kg) + platelet transfusion

15 Arginine vasopressin (100 and 500 pm) and the PKC activa

16 e effects of intranasal administration of an arginine vasopressin 1A and 1B receptor agonist against

17 (-1)) or continuous intravenous infusions of arginine vasopressin (3 pmol.kg(-1).min(-1)), the select

18 1-Deamino-8-D-arginine vasopressin (a V2 receptor agonist, 0.1 nM) sim

19 The patch-clamp technique was used to record arginine vasopressin activation of nonselective cation c

20 in was measured immediately before exogenous arginine vasopressin administration in 10 patients; only

21 After 1-desamino-8-d-arginine-vasopressin administration or water deprivation

22 for melanin concentrating hormone, oxytocin, arginine vasopressin, agouti-related protein and alpha-m

23 opment and activity of anterior hypothalamic arginine vasopressin (AH-AVP).

24 costerone and the vasotocin receptor agonist arginine vasopressin, alone and in combination, on the s

25 Arginine vasopressin also may directly and adversely aff

26 , but the latter conferred responsiveness to arginine-vasopressin (an inhibitory PKC-dependent respon

27 urine after the treatment of desamino-cis, D-arginine vasopressin, an antidiuretic hormone.

28 to test the memory-enhancing effects of the arginine vasopressin analog [pGlu4, Cyt6] AVP (4-8) at a

29 fluid accumulation was partially reduced by arginine vasopressin and almost completely blocked by se

30 isual sources and contains neurons producing arginine vasopressin and calretinin.

31 tightly controlled by the pituitary hormone arginine vasopressin and defective trafficking results i

32 In the laboratory, pairing is regulated by arginine vasopressin and its predominant CNS receptor, v

33 ave determined the structure and function of arginine vasopressin and its receptors, the role of the

34 Arginine vasopressin and norepinephrine are equally effe

35 e action potential E-wave and the release of arginine vasopressin and oxytocin (S-wave).

36 sotocin or isotocin, homologues of mammalian arginine vasopressin and oxytocin that are broadly impli

37 r-mediated von Willebrand factor increase by arginine vasopressin and the potential benefit of select

38 illing induces the nonosmotic stimulation of arginine vasopressin and upregulation of aquaporin 2 fol

39 containing two peptides found in SCN cells, arginine vasopressin and vasoactive intestinal polypepti

40 sses of peptidergic neurons in the SCN: AVP (arginine vasopressin) and VIP (vasoactive intestinal pol

41 -adrenomedullin, CT-pro-endothelin-1, CT-pro-arginine vasopressin, and MR-pro-atrial natriuretic pept

42 In contrast, pressor hormones like arginine-vasopressin, angiotensin II, and endothelin bin

43 Expression of oxytocin, oxytocin receptor, arginine vasopressin, arginine vasopressin V1a receptors

44 leasing factor (CRF) (0.5 microg kg(1)) plus arginine vasopressin (AVP) (0.1 microg kg(1)).

45 Defining how arginine vasopressin (AVP) acts centrally to regulate ho

46 Arginine vasopressin (AVP) affects kidney function via v

47 rs tonically inhibit the secretion of renin, arginine vasopressin (AVP) and adrenocorticotropic hormo

48 PVN) corticotrophin releasing hormone (CRH), arginine vasopressin (AVP) and anterior pituitary proopi

49 study was undertaken to define the impact of arginine vasopressin (AVP) and atrial natriuretic peptid

50 In addition, plasma arginine vasopressin (AVP) and atrial natriuretic peptid

51 partial colocalization with the neuropeptide arginine vasopressin (AVP) and clock proteins (PER2 and

52 rotransmitter function for the neuropeptides arginine vasopressin (AVP) and corticotropin releasing f

53 role for VIP augmented by contributions from arginine vasopressin (AVP) and gastrin-releasing peptide

54 tated urea transport is regulated acutely by arginine vasopressin (AVP) and hyperosmolality in rat te

55 lar response to the neurohypophyseal hormone arginine vasopressin (AVP) and in the expression of oxid

56 lationship between cerebrospinal fluid (CSF) arginine vasopressin (AVP) and indices of aggression and

57 Arginine vasopressin (AVP) and its type-2 receptor (V2R)

58 The neuropeptides arginine vasopressin (AVP) and oxytocin (OT) are key mod

59 Arginine vasopressin (AVP) and oxytocin (OT) influence s

60 voltage-gated Ca(2+) channel currents and on arginine vasopressin (AVP) and oxytocin (OT) release fro

61 pophysial nerve terminals, the neurohormones arginine vasopressin (aVP) and oxytocin (OT) undergo Ca(

62 Arginine vasopressin (AVP) and related peptides affect s

63 e paraventricular nucleus (PVN) that release arginine vasopressin (AVP) and specifically, that increa

64 o examine the renal effects of a V2 receptor arginine vasopressin (AVP) antagonist in heart failure.

65 Circulating levels of arginine vasopressin (AVP) are elevated during hypovolem

66 Corticotropin-releasing hormone (CRH) and arginine vasopressin (AVP) are pivotal mediators of the

67 o (BB) rat with CDI, the mRNA and protein of arginine vasopressin (AVP) are present in the hypothalam

68 Oxytocin (OT) and arginine vasopressin (AVP) are two small, related neurop

69 This was dependent on the neuropeptide arginine vasopressin (AVP) because it was prevented by p

70 oro rats were treated with a 5-d infusion of arginine vasopressin (AVP) by osmotic minipump, the 117-

71 f corticotrophin-releasing hormone (CRH) and arginine vasopressin (AVP) cause a depolarization of cor

72 r characterized by post-natal development of arginine vasopressin (AVP) deficiency due to mutations i

73 ne vasotocin (AVT) and its mammalian homolog arginine vasopressin (AVP) demonstrate several relations

74 Arginine vasopressin (AVP) enhances water reabsorption i

75 In A7r5 cells, arginine vasopressin (AVP) evoked a striking Ca(2+) entr

76 Secretion of the neuropeptide arginine vasopressin (AVP) from the neurohypophysis is o

77 (Hom) rats, which contain a mutation in the arginine vasopressin (AVP) gene, exhibit lower behaviora

78 etes insipidus is caused by mutations in the arginine vasopressin (AVP) gene.

79 Arginine vasopressin (AVP) has a key role in osmoregulat

80 Recently, the mammalian neuropeptide arginine vasopressin (AVP) has been implicated in aggres

81 on corticotropin-releasing factor (CRF) and arginine vasopressin (AVP) heteronuclear RNA (hnRNA) exp

82 more subtle, although reliable, increase in arginine vasopressin (AVP) hnRNA in this same compartmen

83 The role of arginine vasopressin (AVP) in the nongenomic transfer of

84 DI results from a deficiency of the hormone arginine vasopressin (AVP) in the pituitary gland or the

85 e interaction of 5-HT receptor agonists with arginine vasopressin (AVP) in the regulation of offensiv

86 er2, and mCry1 and the clock-controlled gene arginine vasopressin (AVP) in the SCN.

87 e, the synthesis of the antidiuretic hormone arginine vasopressin (AVP) increases in the hypothalamus

88 Exposure of vascular smooth muscle cells to arginine vasopressin (AVP) increases smooth muscle alpha

89 There is ample evidence that arginine vasopressin (AVP) is a component of the neuroho

90 Arginine vasopressin (AVP) is a neurohypophysial hormone

91 Arginine vasopressin (AVP) is a vasoactive hormone that

92 ues corticotropin-releasing factor (CRF) and arginine vasopressin (AVP) is not clear.

93 Arginine vasopressin (AVP) is often expressed in small c

94 Arginine vasopressin (AVP) is present in both magnocellu

95 ) concentration of the "social" neuropeptide arginine vasopressin (AVP) is significantly lower in ped

96 Arginine vasopressin (AVP) levels are elevated in propor

97 ability accompanied by elevated circulating arginine vasopressin (AVP) levels in SHR-A3 compared wit

98 presence of SIADH, yet who had undetectable arginine vasopressin (AVP) levels.

99 c corticotrophin-releasing hormone (CRH) and arginine vasopressin (AVP) messenger and heteronuclear R

100 vasotocin (AVT) and its mammalian homologue arginine vasopressin (AVP) modulate reproduction-related

101 The neuropeptide arginine vasopressin (AVP) modulates a variety of specie

102 in-releasing hormone (CRH) and parvocellular arginine vasopressin (AVP) mRNA expression relative to s

103 Corticotropin releasing factor (CRF) and arginine vasopressin (AVP) mRNA levels were analyzed by

104 of corticotropin-releasing factor (CRF) and arginine vasopressin (AVP) mRNAs in the paraventricular

105 of corticotropin-releasing factor (CRF) and arginine vasopressin (AVP) mRNAs, the primary hypothalam

106 related with the enhanced development of the arginine vasopressin (AVP) neural system and reduced dev

107 on of the pituitary, which contains axons of arginine vasopressin (AVP) neurons from the hypothalamic

108 ic cells of the SCN, including VIP, GRP, and arginine vasopressin (AVP) neurons, with each ipRGC inne

109 of centrally administered oxytocin (OT) and arginine vasopressin (AVP) on partner preference formati

110 e PVT-projecting SCN cells containing either arginine vasopressin (AVP) or gastrin releasing peptide

111 nd revealed circadian neurons that contained arginine vasopressin (AVP) or vasoactive intestinal poly

112 The neuropeptide arginine vasopressin (AVP) plays significant roles in ma

113 dominant disorder caused by mutations in the arginine vasopressin (AVP) precursor.

114 rder caused by a variety of mutations in the arginine vasopressin (AVP) precursor.

115 oping hyponatremia from numerous stimuli for arginine vasopressin (AVP) production, such as volume de

116 sed that a self-assembling lipidized peptide arginine vasopressin (AVP) receptor agonist, that had no

117 Synthetic arginine vasopressin (AVP) receptor agonists able to ind

118 Arginine vasopressin (AVP) regulates fluid balance and b

119 Arginine vasopressin (AVP) regulates the osmotic water p

120 ogen lowers the plasma osmotic threshold for arginine vasopressin (AVP) release but without commensur

121 rdinates autonomic responses in part through arginine vasopressin (AVP) released in medial nucleus tr

122 Arginine vasopressin (AVP) represents a potentially attr

123 Glucopenia stimulates neurohypophyseal arginine vasopressin (AVP) secretion and expression of t

124 duce a parallel increase in water intake and arginine vasopressin (AVP) secretion to promote fluid ex

125 ted adrenocorticotropin (ACTH), cortisol and arginine vasopressin (AVP) secretion, responses that wer

126 Arginine vasopressin (AVP) stimulates the release of ent

127 rincipal cells of the renal collecting duct, arginine vasopressin (AVP) stimulates the synthesis of c

128 , corticotrophin-releasing hormone (CRH) and arginine vasopressin (AVP) to control the release of adr

129 , corticotrophin-releasing hormone (CRH) and arginine vasopressin (AVP) to control the release of adr

130 Deficiency of the antidiuretic hormone arginine vasopressin (AVP) underlies diabetes insipidus,

131 eported d[Cha(4)]AVP were evaluated on human arginine vasopressin (AVP) V(1a), V(1b), and V(2) recept

132 blocking agent hexamethonium (5 mg/kg) or an arginine vasopressin (AVP) V1 receptor antagonist (AVPX,

133 astrated males injected centrally with mixed arginine vasopressin (AVP) V1a/b receptor antagonists da

134 Arginine vasopressin (AVP) V2 receptor antagonists inhib

135 d or decreased in these mice, whereas plasma arginine vasopressin (AVP) was increased, supporting a r

136 d doses of phenylephrine, angiotensin II and arginine vasopressin (AVP) were determined at 124 +/- 1

137 ling reveal three distinct binding sites for arginine vasopressin (AVP) within its V2 -receptor (V2 R

138 Here we show that arginine vasopressin (AVP), a neuropeptide that mediates

139 of serum osmolality and serum sodium, plasma arginine vasopressin (AVP), and plasma copeptin concentr

140 he SCN shell contain GABA, calbindin (CALB), arginine vasopressin (AVP), angiotensin II (AII) and met

141 eptide neuromedin U (NMU), or are related to arginine vasopressin (AVP), both of which have PRXa moti

142 er 1-day hypothermia during the perfusion of arginine vasopressin (AVP), D-arginine (D-ARG), L-argini

143 Arginine vasopressin (AVP), or antidiuretic hormone, is

144 anglia with forskolin, isoproterenol (IPNE), arginine vasopressin (AVP), or papaverine, all of which

145 ntrations of copeptin, a surrogate marker of arginine vasopressin (AVP), to be associated with increa

146 vasoactive intestinal polypeptide (VIP) and arginine vasopressin (AVP), using in situ hybridization.

147 Renal water reabsorption is controlled by arginine vasopressin (AVP), which binds to V2 receptors,

148 inal peptide (VIP)-expressing cells, but not arginine vasopressin (AVP)-expressing cells, exhibited s

149 able experimental results that indicate that arginine vasopressin (AVP)-independent factors are invol

150 a (or both) were the enzymes responsible for arginine vasopressin (AVP)-induced AA release from A-10

151 Catalase substantially attenuated arginine vasopressin (AVP)-induced Ca(2+) entry in cells

152 Because cAMP is a central modulator of arginine vasopressin (AVP)-induced water transport in th

153 correlate with a reduction of parvocellular arginine vasopressin (AVP)-positive neurons in the preop

154 ocalized on the plasma membrane and mediates arginine vasopressin (AVP)-stimulated cAMP accumulation,

155 A V2R, as was the concentration response for arginine vasopressin (AVP)-stimulated cAMP accumulation.

156 smooth muscle cells and blocks induction by arginine vasopressin (AVP).

157 93 cells was phosphorylated after binding to arginine vasopressin (AVP).

158 sis and release of the neuropeptide hormone, arginine vasopressin (AVP).

159 examined the responsiveness of the kidney to arginine vasopressin (AVP).

160 Here, we report that serotonin (5-HT) and arginine-vasopressin (AVP) act in opposite ways in the h

161 In vascular smooth muscle cells, arginine-vasopressin (AVP) activated non-selective catio

162 he context of differences among the lines in arginine-vasopressin (AVP) and light-induced Fos express

163 nonpaternal voles (microtus) have different arginine-vasopressin (AVP) and oxytocin (OT) receptor pa

164 Arginine-vasopressin (AVP) binding to vasopressin V2 rec

165 The distribution of arginine-vasopressin (AVP) cells in the SCN overlapped w

166 Our experience in adults prompted the use of arginine-vasopressin (AVP) in a similar group of critica

167 onatremic patients have elevated circulating arginine-vasopressin (AVP) levels, we examined whether A

168 suprachiasmatic nucleus output neuropeptide arginine-vasopressin (AVP) on the activity of preoptic a

169 d physiology of thirst, taste for water, and arginine-vasopressin (AVP) release: ( a) Thirst and AVP

170 olvement of different groups of hypothalamic arginine-vasopressin (AVP) synthesizing neurons in multi

171 In golden hamsters, microinjections of arginine-vasopressin (AVP) within the anterior hypothala

172 ization of Fos expression and oxytocin (OT), arginine-vasopressin (AVP), corticotrophin-releasing fac

173 tances corticotropin-releasing factor (CRF), arginine-vasopressin (AVP), histidine decarboxylase (HDC

174 owed by an antibody to either oxytocin (OT), arginine-vasopressin (AVP), or corticotropin releasing h

175 Levels of hypophysial portal arginine-vasopressin (AVP), plasma ACTH and plasma corti

176 We evaluated contraction (KCl and arginine vasopressin [AVP]) and dilation (acetylcholine

177 for MT, OT, and the mammalian AVT homologue, arginine vasopressin [AVP]).

178 1a receptor/vasopressin V2 receptor agonist arginine vasopressin because of its lack of agonist acti

179 Patients with plasma arginine vasopressin below the lower quartile (< 9.2 pg/

180 B, neurotensin, gastrin, cholecystokinin and arginine vasopressin bind seven transmembrane-spanning r

181 is is the first study that demonstrates that arginine vasopressin boosts placebo effects and that the

182 We did not detect major deficiencies in arginine vasopressin [Ca(2+)](i) signaling in split-open

183 Arginine vasopressin colocalized with EGFP more often in

184 ynamic instability and relatively low plasma arginine vasopressin concentration (< 9.2 pg/mL) had not

185 ildren undergoing open heart surgery, plasma arginine vasopressin concentration is relatively low at

186 rebral magnetic resonance imaging, and serum arginine vasopressin concentration) were compatible with

187 iopulmonary bypass for measurement of plasma arginine vasopressin concentration.

188 in, melanin-concentrating hormone, oxytocin, arginine vasopressin, corticotropin-releasing hormone (C

189 The glutamine(4) residue in [deamino-Cys(1)]arginine vasopressin (dAVP) was replaced by a broad seri

190 Administration of 1-desamino-8-D-arginine vasopressin (DDAVP) causes a rapid, concomitant

191 In response to 1-desamino-8-D-arginine vasopressin (DDAVP), peak VWF:Ag levels exceede

192 ximum antidiuresis produced by 1-deamino-8-D-arginine vasopressin (DDAVP).

193 Infusion of 1-deamino-(8-D-arginine)-vasopressin (dDAVP), a vasopressin V2 receptor

194 Administration of 1-desamino-8-D-arginine-vasopressin (DDAVP) to patients with type 1 von

195 he first study, two groups of 1-deamino-[8-D-arginine]-vasopressin (dDAVP)-infused rats were water-lo

196 Desmopressin (1-deamino-8-d-arginine vasopressin [DDAVP]) releases stored VWF and FV

197 ins (Saccharomyces cerevisiae) that required arginine vasopressin-dependent receptor/G protein coupli

198 termine whether deletion of GSK3beta affects arginine vasopressin-dependent renal water reabsorption.

199 1-deamino-8-d-arginine vasopressin (desmopressin [DDAVP]) is clinicall

200 corticotropin-releasing hormone-dominant to arginine vasopressin-dominant, and cortisol levels remai

201 se to locally applied phenylephrine, Ang II, arginine vasopressin, elevated [K(+)]o and acetylcholine

202 ses of the basilar artery to angiotensin II, arginine vasopressin, endothelin-1 and U-46619.

203 kg i.p.) rats in response to angiotensin II, arginine vasopressin, endothelin-1, and the thromboxane

204 is strongly stimulated immediately following arginine-vasopressin exposure of H9c2 ventricular myocyt

205 With arginine vasopressin, five of five animals survived 300

206 riptional regulation of the clock-controlled arginine vasopressin gene in the suprachiasmatic nuclei

207 ucleotide deletion in the second exon of the arginine vasopressin gene, resulting in the synthesis of

208 ivity of other GPCR agonists, including ADP, arginine vasopressin, glucagon-like peptide 1, and forsk

209 Hb ratio was lower in the FE 202158 than the arginine vasopressin group (p < .005).

210 n the desmopressin (40 +/- 6%, p < .001) and arginine vasopressin groups (25 +/- 4%, p < .001).

211 Arginine vasopressin has been implicated in the renal wa

212 t the SCN, including a limited population of arginine vasopressin-immunoreactive (AVP-IR) neurons.

213 ents were designed to evaluate whether early arginine vasopressin improves acute outcome following re

214 Mean plasma arginine vasopressin in group B was 104 +/- 160 at 4 hrs

215 d by the V2 receptor agonist (1-desamino-8-D-arginine vasopressin) in wild-type mice, is lacking in k

216 The V2 receptor agonist 1-deamino-8-d-arginine vasopressin increased renal cAMP and recovered

217 Here we show that centrally administered arginine vasopressin increases affiliative behaviour in

218 Arginine vasopressin influences male reproductive and so

219 Compared with controls, arginine vasopressin infusion improved myocardial functi

220 ular functions and tissue oxygenation, while arginine vasopressin infusion may only improve blood pre

221 However, with phenylephrine vs. arginine vasopressin, intracranial pressure averaged >10

222 os-IR within the SCN overlapped with that of arginine-vasopressin-IR (AVP-IR) and vasoactive intestin

223 We tested the hypothesis that arginine vasopressin is a suitable alternative to norepi

224 l and the secretion of antidiuretic hormone (arginine vasopressin) is fully suppressed, the human kid

225 Although the native hormone arginine-vasopressin leads to activation of both the sti

226 Arginine vasopressin levels are elevated in infants and

227 tent, lactate, pH, standard base excess, and arginine vasopressin levels were determined, and systemi

228 /-) mice developed polyuria despite elevated arginine vasopressin levels.

229 In addition, we found a gene encoding an arginine-vasopressin-like (AVPL) peptide and one for its

230 or all known insect neuropeptides except for arginine-vasopressin-like peptide (AVLP), CNMamide, neur

231 The peptide arginine-vasopressin (mammals) and its evolutionary prec

232 Arginine vasopressin may contribute to abnormalities in

233 a ryanodine receptor antagonist, blocked the arginine vasopressin-mediated increase in P(f) and block

234 sed the corticotrophin-releasing hormone and arginine vasopressin mRNA as well as the corticosterone

235 In contrast, arginine vasopressin mRNA was detected in only five of t

236 y 300 mins after traumatic brain injury with arginine vasopressin (n = 8) vs. placebo (n = 8), the fl

237 ally unchanged from its baseline mean plasma arginine vasopressin of 5.0 +/- 10.4 (p = .977).

238 Mean plasma arginine vasopressin of group A was also significantly l

239 ection of neurogenic hypotension with either arginine vasopressin or norepinephrine limits edema, red

240 neurons within the PVN also contained either arginine vasopressin or oxytocin.

241 otropin-releasing hormone and do not express arginine vasopressin or oxytocin.

242 blood with either 0.1 unit x kg(-1) x hr(-1) arginine vasopressin or placebo was titrated to a mean a

243 vel, an additional continuous IV infusion of arginine vasopressin or selepressin was titrated to rais

244 fails to secrete neuropeptides somatostatin, arginine vasopressin, oxytocin, corticotropin-releasing

245 sexual antagonism acting on loci within the arginine vasopressin-oxytocin pathway explains how genet

246 Plasma arginine vasopressin (pAVP), which is inhibited by psych

247 Mean plasma arginine vasopressin (pg/mL) for all patients was 21 +/-

248 Treatment with 1-deamino-8-D-arginine vasopressin + platelet transfusion was not asso

249 Copeptin is a stable arginine vasopressin precursor associated with increased

250 sponsible for the clearance of misfolded pro-arginine vasopressin (proAVP) in the ER.

251 of corticotropin, norepinephrine, cortisol, arginine vasopressin, prolactin, corticotropin-releasing

252 Early supplemental arginine vasopressin rapidly corrected cerebral perfusio

253 The V1a arginine vasopressin receptor (V1aR) expressed in HEK 29

254 Expression of arginine vasopressin receptor 1a (Avpr1a) and oxytocin r

255 ts of a single 20 mg intravenous dose of the arginine vasopressin receptor 1A (V1a) antagonist, RG771

256 ndem repeats RS1, RS3 and AVR in the AVPR1A (arginine vasopressin receptor 1a) gene and STin2 in the

257 8396 single-nucleotide polymorphism near the arginine vasopressin receptor 1b gene is associated with

258 396 single-nucleotide polymorphism (near the arginine vasopressin receptor 1b gene) was significantly

259 urine concentration mechanism by modulating arginine vasopressin receptor 2 and AQP2 expression in t

260 east in part, to decreased expression of the arginine vasopressin receptor 2 in ptip mutants.

261 reproprotein, the oxytocin receptor, and the arginine vasopressin receptor contain VDREs for activati

262 and excellent selectivity against the human arginine vasopressin receptors.

263 Low-dose arginine vasopressin reduced nitrosative stress and impr

264 mic function and tissue oxygenation, whereas arginine vasopressin resuscitation improves blood pressu

265 arance without a concomitant increase in the arginine vasopressin serum levels.

266 groups without a concomitant increase in the arginine vasopressin serum levels.

267 likely the optimal candidates for exogenous arginine vasopressin should hemodynamic compromise occur

268 al hemorrhage studies, adjunct 1-deamino-8-D-arginine vasopressin showed no benefit in limiting hemat

269 Here, we show that arginine vasopressin specifically activates interneurons

270 Upon arginine vasopressin stimulation, this chimeric receptor

271 s RXFP3-mediated inhibition of oxytocin- and arginine-vasopressin-synthesizing paraventricular nucleu

272 receptor/vasopressin type 2 receptor agonist arginine vasopressin, the selective vasopressin type 1a

273 clude corticotropin-releasing hormone (CRH); arginine vasopressin; the proopiomelanocortin-derived pe

274 i, human adipocytes were treated with KCl or arginine vasopressin to stimulate voltage- and receptor-

275 -24 hrs; p </= .001 each) were attenuated in arginine vasopressin-treated animals compared with contr

276 I and muscle perfusion by 42% and 51%, while arginine vasopressin treatment reduced heart rate by 31%

277 ased fluid accumulation to levels similar to arginine vasopressin treatment.

278 AVP activates arginine vasopressin type 1A (V(1A))/Galpha(q)-coupled r

279 gic receptor with the C-terminal tail of the arginine vasopressin type 2 receptor (beta(2)V(2)R).

280 The arginine-vasopressin type 2 receptor (V2R), a prototypic

281 s of fluorescent benzazepine ligands for the arginine-vasopressin V(2) receptor (AVP V(2)R) was synth

282 rons project from the PVN to the RVLM and if arginine vasopressin (V(1A)) receptor expression increas

283 least in part, by changes in the density of arginine vasopressin-V(1a) receptors (V(1a)R).

284 ion of a ganglion blocking agent, but not an arginine vasopressin V1 receptor antagonist, lowered blo

285 The arginine vasopressin V1a receptor gene (AVPR1A) has been

286 in, oxytocin receptor, arginine vasopressin, arginine vasopressin V1a receptors, and corticotrophin-r

287 The arginine vasopressin/vasotocin (AVP/AVT) system is stron

288 In many vertebrates, the arginine vasopressin (VP) innervation of the forebrain,

289 In series 2, with arginine vasopressin vs. placebo, cerebral perfusion pre

290 Mean plasma arginine vasopressin was 4.9 +/- 2.6 in group A at 4 hrs

291 Arginine vasopressin was as effective as phenylephrine f

292 The hypothesis was that arginine vasopressin was as effective as phenylephrine f

293 Plasma arginine vasopressin was measured immediately before exo

294 ion of femoral arterial rings in response to arginine vasopressin was significantly enhanced in both

295 After 120 mins, phenylephrine or arginine vasopressin was titrated to cerebral perfusion

296 lality after administration of 1-deamino-8-D-arginine-vasopressin was approximately 700 mosm/kg H(2)O

297 Plasma renin activity, aldosterone and arginine vasopressin were also significantly decreased i

298 s doses of phenylephrine, angiotensin II and arginine vasopressin were recorded.

299 Conversely, responses to KCl or arginine vasopressin were unaffected.

300 However, the 24 hr rhythms of arginine vasopressin within the SCN and plasma corticost